脳障害と治療

概要

The genomics of dopamine agonist

Puja Patel

We present the instance of a patient with antipsychotics nonresponsive negative side effects of Schizophrenia who reacted essentially to a dopamine agonist inside six days of treatment. He was already lethargic to other psychotropic drugs. Genomic testing of the patient uncovered a Homozygous Valine Catechol-O-Methyltransferase (COMT) polymorphism which is related with elevated ability to burn calories of dopamine in the frontal cortex with resulting low dopamine action. The centrality of this finding for choosing great possibility for psychostimulant treatment for negative side effects is examined.